Safety Assessment of Femoropopliteal Endovascular Treatment With PAclitaxel-coated Devices (SAFE-PAD Study) (SAFE-PAD)
Sponsor: Bard Peripheral Vascular, Inc.
This observational or N/A phase trial investigates Paclitaxel Adverse Reaction and Peripheral Arterial Disease and is currently completed. Bard Peripheral Vascular, Inc. leads this study, which shows 6 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting
-
Jun 2023 — Jul 2024 [monthly]
Active Not Recruiting
-
Apr 2022 — Jun 2023 [monthly]
Active Not Recruiting
-
Jan 2021 — Apr 2022 [monthly]
Active Not Recruiting
▶ Show 1 earlier version
-
Sep 2020 — Jan 2021 [monthly]
Active Not Recruiting
First recorded
Jul 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bard Peripheral Vascular, Inc.
- Beth Israel Deaconess Medical Center
- Boston Scientific Corporation
- Cook Medical
- Medtronic
- Philips Healthcare
For direct contact, visit the study record on ClinicalTrials.gov .